nanoantibodies therapy (Allele Biotechnology & Pharmaceuticals)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namenanoantibodies therapy (Allele Biotechnology & Pharmaceuticals)

Drug Alias NameSARS-CoV-2 S-protein targeted neutralizing nanobodies (Allele Biotechnology)nanoantibodies targeting SARS-CoV-2 spike protein S1 (Allele Biotechnology)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody

Mechanisms of ActionCoronavirus spike glycoprotein inhibitors

TargetsCoronavirus spike glycoprotein

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAllele Biotechnology and Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAllele Biotechnology and Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A